Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 796073-69-3 Chemical Structure| 796073-69-3

Structure of DM4
CAS No.: 796073-69-3

Chemical Structure| 796073-69-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Maytansinoid DM4 is a tubulin inhibitor, inhibits the assemblyof microtubules by binding to tubulin, with a linker structure can create an antibody-drug conjugate (ADC).

Synonyms: Maytansinoid DM 4

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of DM4

CAS No. :796073-69-3
Formula : C38H54ClN3O10S
M.W : 780.37
SMILES Code : C[C@]1([C@H](CC(N(C(C=C2C=C3OC)=C3Cl)C)=O)OC([C@H](C)N(C)C(CCC(C)(S)C)=O)=O)[C@H]([C@@H]([C@](OC4=O)([H])C[C@]([C@](/C=C/C=C(C)/C2)([H])OC)(N4)O)C)O1
Synonyms :
Maytansinoid DM 4
English Name :(14S,16S,32S,33S,2R,4S,10E,12E,14R)-86-Chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-(4-mercapto-4-methylpentanoyl)-N-methyl-L-alaninate
MDL No. :MFCD28144516

Safety of DM4

Related Pathways of DM4

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Microtubule protein 100 nmol/L 40 minutes To evaluate the effect of DM4 on microtubule dynamic instability, results showed that DM4 significantly suppressed microtubule dynamic instability, reducing the shortening rate by 56% and dynamicity by 73%. Mol Cancer Ther. 2010 Oct;9(10):2689-99
Microtubule protein 0 – 20 μmol/L 45 minutes To evaluate the inhibitory effect of DM4 on microtubule polymerization, results showed that DM4 inhibited microtubule polymerization at 1.7 ± 0.4 μmol/L. Mol Cancer Ther. 2010 Oct;9(10):2689-99
NXS2 cells 3nM 72 hours To evaluate the effect of DM4 on PD-L1 expression, results showed that DM4 significantly upregulated the surface expression of PD-L1. J Transl Med. 2025 Apr 11;23(1):431
NXS2 cells 5nM 72 hours To assess the ability of DM4 to induce immunogenic cell death (ICD), results showed that DM4 significantly upregulated the expression of calreticulin, HSP70, and HSP90. J Transl Med. 2025 Apr 11;23(1):431
NXS2 CTRL and NXS2 hLGALS3BP cells 0.00064nM to 250nM 72 hours To evaluate the cytotoxic effect of DM4 on neuroblastoma cells, results showed that DM4 exhibited potent cytotoxic activity with an IC50 in the nanomolar range (0.32 nM). J Transl Med. 2025 Apr 11;23(1):431

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CB-17/SCID mice END(K)265 xenograft model Intravenous injection 5 mg/kg Once weekly for two doses IMGN853 showed significant tumor growth inhibition (p<0.01) and complete tumor resolution Mol Cancer Ther. 2018 May;17(5):1003-1011
BALB/c nude mice HT-29, HCT116 and HCT15 xenograft models Intravenously 5 and 10 mg/kg Three injections, every 3 days Evaluate the antitumor efficacy of T4H11-DM4 in xenograft models, complete tumor regression was achieved at doses of 5 and 10 mg/kg in HT-29 and HCT116 tumor models Mol Oncol. 2019 Sep;13(9):1855-1873
Mice A375-MA1 xenograft model Intravenous injection 6.0-6.7 μg Single dose, observed for 120 hours To evaluate the pharmacokinetics and tumor uptake of [89Zr]Zr-DFO-1959-sss/DM4 in the A375-MA1 xenograft model Mol Pharm. 2023 Jun 5;20(6):3241-3248
Nude mice GBM patient-derived xenograft model Intravenous injection 10 mg/kg Twice weekly for a total of three injections Evaluate the antitumor activity of 1959-sss/DM4 in GBM xenograft model Mol Oncol. 2023 Aug;17(8):1460-1473
NOD/SCID/IL-2Rg(null) mice and nude mice PDX and CDX models Tail vein injection 5 mg/kg and 10 mg/kg Once every three days for a total of three doses Anti-DOG1-DM4-ADC significantly inhibited tumor growth Front Immunol. 2023 Jan 26;14:1051506
A/J mice Neuroblastoma model Intravenous injection 10 mg/kg Twice weekly, three total injections To evaluate the antitumor activity of anti-LGALS3BP ADC in a neuroblastoma model, results showed that ADC significantly shrank hLGALS3BP-expressing tumors and improved survival. J Transl Med. 2025 Apr 11;23(1):431

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.28mL

0.26mL

0.13mL

6.41mL

1.28mL

0.64mL

12.81mL

2.56mL

1.28mL

References

 

Historical Records

Categories